S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.[1][2]
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C18H13ClF4N2O3 |
Molar mass | 416.76 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |